Subgroup analyses based on study design, health status, intervention duration, and dosage also failed to reveal any improvement in fasting blood glucose (FBG), homeostatic model assessment of insulin resistance (HOMA-IR), or insulin (INS). The gene discussed is INS; the disease is Insulin resistance.